Webinar Evaluating Drug-Induced Proarrhythmic Risk Using the CardioECR System

free Webinar, Wednesday, March 11, 2015, 04:00 pm CET

Evaluating Drug-Induced Proarrhythmic Risk Using the CardioECR System

Cardiovascular toxicity is a leading cause of drug attrition and withdrawal. There is an urgent need for more predictive and higher throughput assays that could provide mechanistic toxicity information and could be implemented earlier in the drug discovery and development process.

In this webinar, Dr. Zeng, a Principal Scientist at Merck Research Laboratories, will discuss his work utilizing the new xCELLigence RTCA CardioECR system in conjunction
with iPSC cardiomyocytes to assess cardiotoxic liabilityof compounds. Specifically, Dr. Zeng will discuss his experience with the CardioECR system and screening of compounds, which are part of the FDA CiPA (Comprehensive in vitro Proarrhythmia Assay) Initiative.

During the webinar, Dr. Zeng will cover:

  • An overview of the in vitro cardio toxicity screening
  • The principle of the CardioECR system – simultaneous monitoring contractility and field potential of cardiomyocytes
  • Results from the CiPA validation study at Merck using the CardioECR system

To register, visit: aceabio.webex.com

UPDATE: Sehen Sie hier das Webinar auf YouTube: https://youtu.be/ae_tvYjOUC4



Passende Artikel

xCELLigence CardioECR

A Comprehensive Solution for in vitro Cardiac Safety Assessment   The xCELLigence RTCA CardioECR System is the first ever platform to combine impedance and field potential recording for simultaneous and noninvasive measurement of integrated ion channel activity and contractility of cardiomyocytes in a 48 well microtiter plate format. The system is designed to be placed in a standard tissue culture incubator with physiological...

Preis auf Anfrage



Kommentar schreiben


Die mit einem * markierten Felder sind Pflichtfelder.